GENMAB AS SP.ADR/1/10DK 1 (F:GE91) — Market Cap & Net Worth
Market Cap & Net Worth: GENMAB AS SP.ADR/1/10DK 1 (GE91)
GENMAB AS SP.ADR/1/10DK 1 (F:GE91) has a market capitalization of $15.06 Billion (€12.88 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #1627 globally and #353 in its home market, demonstrating a -2.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENMAB AS SP.ADR/1/10DK 1's stock price €23.80 by its total outstanding shares 615993070 (615.99 Million). Also see balance sheet size of GENMAB AS SP.ADR/1/10DK 1 for a full breakdown of the balance sheet.
GENMAB AS SP.ADR/1/10DK 1 Market Cap History: 2020 to 2026
GENMAB AS SP.ADR/1/10DK 1's market capitalization history from 2020 to 2026. Data shows change from $23.21 Billion to $20.31 Billion (-2.39% CAGR). Also see GE91 operating cash flow for how efficiently the company converts equity into cash flow.
GENMAB AS SP.ADR/1/10DK 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENMAB AS SP.ADR/1/10DK 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GENMAB AS SP.ADR/1/10DK 1 (GE91) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.30x
GENMAB AS SP.ADR/1/10DK 1's market cap is 5.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.49x
GENMAB AS SP.ADR/1/10DK 1's market cap is 20.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $25.21 Billion | $1.28 Billion | $450.16 Million | 19.67x | 55.99x |
| 2022 | $28.66 Billion | $2.09 Billion | $784.70 Million | 13.73x | 36.53x |
| 2023 | $20.74 Billion | $2.39 Billion | $631.00 Million | 8.68x | 32.87x |
| 2024 | $14.40 Billion | $3.12 Billion | $1.13 Billion | 4.61x | 12.71x |
| 2025 | $19.73 Billion | $3.72 Billion | $963.00 Million | 5.30x | 20.49x |
Competitor Companies of GE91 by Market Capitalization
Companies near GENMAB AS SP.ADR/1/10DK 1 in the global market cap rankings as of September 16, 2026. Review how tangible is GENMAB AS SP.ADR/1/10DK 1's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GENMAB AS SP.ADR/1/10DK 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
GENMAB AS SP.ADR/1/10DK 1 Historical Marketcap From 2020 to 2026
Between 2020 and today, GENMAB AS SP.ADR/1/10DK 1's market cap moved from $23.21 Billion to $ 20.31 Billion, with a yearly change of -2.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €20.31 Billion | +2.92% |
| 2025 | €19.73 Billion | +37.00% |
| 2024 | €14.40 Billion | -30.56% |
| 2023 | €20.74 Billion | -27.64% |
| 2022 | €28.66 Billion | +13.71% |
| 2021 | €25.21 Billion | +8.59% |
| 2020 | €23.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GENMAB AS SP.ADR/1/10DK 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.06 Billion USD |
| MoneyControl | $15.06 Billion USD |
| MarketWatch | $15.06 Billion USD |
| marketcap.company | $15.06 Billion USD |
| Reuters | $15.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more